Top Markets
#1 Black Phoenix Black Phoenix +737.06%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +25.03%
#3 Wrapped STX (Velar) Wrapped STX (Velar) +18.54%
#4 MetaDAO MetaDAO +15.56%
#5 Verus Coin Verus Coin +13.88%
#6 THORChain THORChain +10.94%
#7 The Bitcoin Bull The Bitcoin Bull +9.93%
#8 TENDIES TENDIES +9.88%
#9 PondCoin PondCoin +8.82%
#10 Akedo Akedo +8.29%
Coin of the day
Black Phoenix Black Phoenix
Innstillinger
Språk
NORSK
Valuta
USD
Tema
MBX Biosciences, Inc. Common Stock MBX Biosciences, Inc. Common Stock

MBX Biosciences, Inc. Common Stock

MBX
Rangering i aksjer #4857
MBX Biosciences, Inc. is a biopharmaceutical company in its clinical... MBX Biosciences, Inc. is a biopharmaceutical company in its clinical development phase, dedicated to pioneering precise peptide-based therapies for endocrine and metabolic conditions. Its most advanced drug candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in Phase 2 clinical trials. This medication is being evaluated as a long-duration hormone replacement treatment for individuals suffering from chronic hypoparathyroidism. The company is also progressing with MBX 1416, a prolonged-action glucagon-like peptide-1 (GLP-1) receptor antagonist, which is undergoing Phase 1 clinical assessment. The aim of this therapy is to address post-bariatric hypoglycemia, a persistent complication often seen after weight-loss surgery. Furthermore, MBX Biosciences is developing MBX 4291, a key candidate for obesity treatment. This highly potent and long-acting prodrug functions as a co-agonist for both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. It is currently in investigational new drug (IND)-enabling studies, with the intention of treating obesity and its associated health issues. Founded in 2018, the company's operations are headquartered in Carmel, Indiana.
Aksjekurs
$67.63
Sist synkronisert: 2026-08-26
Markedsverdi
$3.22B
Endring (1 dag)
-1.45%
Endring (1 år)
372.57%
Land
US
Handel MBX Biosciences, Inc. Common Stock (MBX)

Kategori

Healthcare
P/E-forhold for MBX Biosciences, Inc. Common Stock (MBX)
P/E-forhold per 2026 TTM: 0
Ifølge MBX Biosciences, Inc. Common Stock sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/E-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet en P/E på 0.
P/E-forholdshistorikk for MBX Biosciences, Inc. Common Stock fra 2026 til 2026
P/E-forhold ved slutten av hvert år
År P/E-forhold Endre
Ikke nok data for de angitte datoene.
P/E-forhold for lignende selskaper eller konkurrenter
Selskap P/E-forhold Forskjell i P/E-forhold Land
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 29.20 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 30.62 -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 -7.93 -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 32.46 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Hvordan lese en P/E-ratio?

Pris/inntjening-forholdet (P/E) måler forholdet mellom aksjekursen og inntjening per aksje.
En lav men positiv P/E indikerer høy inntjening sammenlignet med nåværende verdsettelse, og kan tyde på at selskapet er undervurdert. En høy negativ (nær 0) P/E indikerer store tap.

Selskaper med P/E over 30 eller negativ betraktes vanligvis som "vekstaksjer", hvor investorer forventer vekst eller fremtidig lønnsomhet.

Selskaper med en positiv P/E under 10 anses vanligvis som "verdiaksjer", det vil si at selskapet allerede er lønnsomt, men har begrenset vekstpotensial.